Many patients had high-risk CLL characteristics (unmutated IGHV, 82%; TP53 mutation or del(17p), 60%; or complex karyotype, 47%), and 15/47 (32%) had a documented BTK mutation prior to enrolment. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.